A Study of Zidovudine in Infants Exposed to the HIV Before or Soon After Birth
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To determine if intravenous (IV) and oral zidovudine (AZT) can be safely given to children
aged 1 day to 3 months who were born to mothers with an HIV infection. Also to determine the
correct dose of AZT for young children. Of a total of 908 pediatric AIDS cases, 78 percent
have acquired HIV infection from a mother with HIV infection or at high risk for acquisition
of HIV, and the number of cases in children is expected to increase over the next several
years. AZT therapy may be effective in altering the course of the disease and decreasing the
high mortality in these children. It is also possible that early intervention with AZT may
prevent the establishment of HIV contracted before, during, or just after birth.
Phase:
Phase 1
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)